2 citations
,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
2 citations
,
April 2007 in “Journal of Labelled Compounds and Radiopharmaceuticals” The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.
1 citations
,
September 2023 in “Prostate International” Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
1 citations
,
February 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Certain interactions help prepare the androgen receptor for pairing and activation, which is important for its role in development and disease.
1 citations
,
May 2021 in “Problemy e̊ndokrinologii” Androgen levels can increase at any age, affecting symptoms like acne, hair loss, and prostate size.
1 citations
,
November 2016 in “Journal of the Dermatology Nurses’ Association” Finasteride treats hair loss but may cause side effects like low libido and dizziness.
1 citations
,
January 2014 in “ScholarWorks - University of Montana (University of Montana)” Finasteride reduces low-grade prostate cancer but may not be beneficial overall.
1 citations
,
August 2013 in “PubMed” Testosterone changes reduce thyroxin levels in rats.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
1 citations
,
January 2004 in “The Internet Journal of Geriatrics and Gerontology” Male pattern baldness is common, treatable, and may be linked to heart disease and prostate cancer.
1 citations
,
August 2002 in “PubMed” Finasteride effectively slowed hair loss and promoted hair growth in Taiwanese men.
1 citations
,
January 2002 in “Yaoxue jinzhan” Finasteride reduces sperm count and affects male reproductive function, while Epristeride does not.
1 citations
,
May 2001 in “Pharmacology & Toxicology” Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
October 2025 in “University of Zadar Institutional Repository” Early hair loss may signal a risk for metabolic syndrome and related health issues.
July 2025 in “Journal of Education Health and Sport” Androgenetic alopecia may indicate higher risk for certain diseases and mental health issues.
January 2025 in “HORMONES” Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
May 2021 in “The FASEB Journal” The research gives new understanding on how human steroid 5α-reductases work and how drugs like finasteride inhibit them, which could help in creating new drugs.
January 2020 in “Figshare” The study explored a possible link between finasteride use and suicide.
January 2018 in “Elsevier eBooks” 5α-reductase-2 deficiency causes ambiguous genitalia at birth and affects male sexual development, but individuals often develop male characteristics at puberty.
June 2017 in “Journal of The American Academy of Dermatology” Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.
October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
March 2015 in “Oncology Times” Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.
November 2013 in “International Journal of Dermatology” New skin lesions on the scrotum or vulva in patients with a history of internal cancer could indicate rare skin metastasis.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
January 2012 in “International Society of Hair Restoration Surgery” Finasteride is effective for hair loss but has controversial side effects.